Notice of Termination of the Recombinant Human Serum Albumin Business
July 21, 2022
Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Hiroaki Ueno; hereinafter, “MTPC”), a member of the Mitsubishi Chemical Group, announced that it has decided to terminate its recombinant human serum albumin business.
MTPC has been discussing with a contract manufacturer about resuming sales of MedwayⓇ Injection 25%, a recombinant human serum albumin preparation. However, as a manufacturing method that can withstand quality maintenance and a stable supply cannot be established, MTPC has decided not to resume supply. In association with this, the business related to manufacturing of recombinant human serum albumin is terminated.
MTPC has been discussing with a contract manufacturer about resuming sales of MedwayⓇ Injection 25%, a recombinant human serum albumin preparation. However, as a manufacturing method that can withstand quality maintenance and a stable supply cannot be established, MTPC has decided not to resume supply. In association with this, the business related to manufacturing of recombinant human serum albumin is terminated.
